TGF-β induces HLA-G expression through inhibiting MIR-152 in gastric cancer cells

Journal of Biomedical Science

Volumn 22, Issue 1, 2015, Pages

  Guan, Zhongzheng ^a,c   Song, Bingtan ^a,b   Liu, Fengjun ^a   Sun, Dong ^a   Wang, Kexin ^a   Qu, Hui ^a  

^a SHANDONG UNIVERSITY   (China)

^b The Third People s Hospital of Liaocheng   (China)

^c BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; HLA G; MIR 152; TGF

Indexed keywords

HLA G ANTIGEN; MICRORNA; MIR 152; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; MIRN152 MICRORNA, HUMAN; RNA; TUMOR MARKER; TUMOR PROTEIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAIN OF FUNCTION MUTATION; GASTRIC CANCER CELL LINE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOSS OF FUNCTION MUTATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STOMACH CANCER; TRANSCRIPTION REGULATION; TUMOR ESCAPE; UPREGULATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HLA-G ANTIGENS; HUMANS; MALE; MICRORNAS; NEOPLASM PROTEINS; RNA, NEOPLASM; STOMACH NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR ESCAPE;

EID: 84949257023     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/s12929-015-0177-4     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011;61:69-90.
2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New Engl J Med. 2006;355:11-20.
3. Otani K, Li X, Arakawa T, Chan FK, Yu J. Epigenetic-Mediated Tumor Suppressor Genes as Diagnostic or Prognostic Biomarkers in Gastric Cancer. 2013.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97.
5. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287.
6. Wang J, Song YX, Wang ZN. Non-coding RNAs in gastric cancer. Gene. 2015;560:1-8.
7. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010;14:1170-9.
8. Zhai R, Kan X, Wang B, Du H, Long Y, Wu H, et al. miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine. 2014;35:11367-73.
9. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, et al. Role of transforming growth factor-β1 in invasion and metastasis in gastric carcinoma. J Clin Oncol. 1999;17:607.
10. Li X, Yue ZC, Zhang YY, Bai J, Xn M, Geng JS, et al. Elevated serum level and gene polymorphisms of TGF-β1 in gastric cancer. J Clin Lab Anal. 2008;22:164-71.
11. Zhang H-J, Qian W-Q, Chen R, Sun Z-Q, Song J-D, Sheng L. New Therapeutic Schedule for Prostatic Cancer-3 Cells with ET-1 RNAi and Endostar. Asian Pacific journal of cancer prevention: APJCP. 2014;15:10079.
12. Cao M, Yie SM, Liu J, Ye S, Xia D, Gao E. Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens. 2011;78:120-8.
13. Du L, Xiao X, Wang C, Zhang X, Zheng N, Wang L, et al. Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Canc Sci. 2011;102:1272-80.
14. Tuncel T, Karagoz B, Haholu A, Ozgun A, Emirzeoglu L, Bilgi O, et al. Immunoregulatory Function of HLA-G in Gastric Cancer. Asian Pacific Journal of Cancer Prevention. 2013;14:7681-4.
15. Castelli EC, Moreau P, Oyae Chiromatzo A, Mendes-Junior CT, Veiga-Castelli LC, Yaghi L, et al. In silico analysis of microRNAS targeting the HLA-G 3′ untranslated region alleles and haplotypes. Hum Immunol. 2009;70:1020-5.
16. Zhu XM, Han T, Wang XH, Li YH, Yang HG, Luo YN, et al. Overexpression of miR-152 leads to reduced expression of human leukocyte antigen-G and increased natural killer cell mediated cytolysis in JEG-3 cells. Am J Obstet Gynecol. 2010;202:592 e1-7.
17. Rudstein-Svetlicky N, Loewenthal R, Horejsi V, Gazit E. HLA-G levels in serum and plasma. Tissue Antigens. 2006;67:111-6.
18. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol. 2011;223:205-18.
19. Liu Y, Zhang P, Li J, Kulkarni AB, Perruche S, Chen W. A critical function for TGF-β signaling in the development of natural CD4+ CD25+ Foxp3+ regulatory T cells. Nat Immunol. 2008;9:632-40.
20. Wang Y, Deng B, Tang W, Liu T, Shen X. TGF-β1 secreted by hepatocellular carcinoma induces the expression of the Foxp3 gene and suppresses antitumor immunity in the tumor microenvironment. Dig Dis Sci. 2013;58:1644-52.
21. Li Z, Zhang LJ, Zhang HR, Tian GF, Tian J, Mao XL, et al. Tumor-Derived Transforming Growth Factor-β is Critical for Tumor Progression and Evasion from Immune Surveillance. Asian Pacific Journal of Cancer Prevention:apjcp. 2014;15:5181-6.
22. Deng B, Zhu JM, Wang Y, Liu TT, Ding YB, Xiao WM, et al. Intratumor hypoxia promotes immune tolerance by inducing regulatory T cells via TGFbeta1 in gastric cancer. PloS one. 2013;8, e63777.
23. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. The FASEB Journal. 2005;19:681-93.
24. Yan W-H. Human leukocyte antigen-G in cancer: are they clinically relevant? Canc Lett. 2011;311:123-30.
25. Zeng X-C, Zhang T, Huang D-H, Wang G-Y, Chen W, Li H, et al. RNA interfering targeting human leukocyte antigen-G enhanced immune surveillance mediated by the natural killer cells on hepatocellular carcinoma. Ann Clin Lab Sci. 2013;43:135-44.
26. Huang J, Wang Y, Guo Y, Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52:60-70.
27. Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, et al. miR-152 controls migration and invasive potential by targeting TGFα in prostate cancer cell lines. The Prostate. 2013;73:1082-9.
28. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2014;33:378-86.